Drug Profile
Research programme: gene therapies - Genethon/Cartesian Therapeutics
Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Genethon; Selecta Biosciences
- Developer Cartesian Therapeutics; Genethon
- Class Gene therapies; Hepatoprotectants
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver disorders
- Discontinued Inborn urea cycle disorders; Muscular dystrophies